Biologics Stocks
Specialized drug development and manufacturing firms focus on large-molecule therapeutics derived from living organisms to treat complex genetic, oncological, and autoimmune conditions. Revenue models hinge on high-barrier intellectual property, long-term clinical trial success, and the navigation of stringent regulatory pathways for cell and gene therapies.
As of Oct 23, 2026, Biologics has 79 US-listed companies worth $1.6T combined. The median member moved +1.5% over the past week; CRL led among the 25 largest at +15.1% and PCVX trailed at -5.0%.
Companies in Biologics
- MRK – Merck & Company Inc, $363B
- AMGN – Amgen Inc, $237B
- GILD – Gilead Sciences Inc, $193B
- PFE – Pfizer Inc, $171B
- DHR – Danaher Corporation, $162B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- BIIB – Biogen Inc, $37B
- ZTS – Zoetis Inc, $33.9B
- WST – West Pharmaceutical Services Inc, $27.7B
- BNTX – BioNTech SE, $22.9B
- ZBH – Zimmer Biomet Holdings Inc, $18.8B
- CRL – Charles River Laboratories, $16.6B
- HALO – Halozyme Therapeutics Inc, $14.1B
- AVTR – Avantor Inc, $11.7B
- TECH – Bio-Techne Corp, $11.4B
- RGEN – Repligen Corporation, $11.3B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- PCVX – Vaxcyte Inc, $9.9B
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, $7.1B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- GRFS – Grifols SA ADR, $5.2B
- LEGN – Legend Biotech Corp, $3.7B
- OGN – Organon & Co, $3.6B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- ADMA – ADMA Biologics Inc, $2.4B
- AXGN – Axogen Inc, $2.2B
- LMAT – LeMaitre Vascular Inc, $2B
- BLFS – BioLife Solutions Inc, $1.9B
- ALVO – Alvotech, $1.9B
- MESO – Mesoblast Ltd, $1.7B
- ATEC – Alphatec Holdings Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- ABSI – Absci Corp, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- IMTX – Immatics NV, $1B
- SVRA – Savara Inc, $1B
- CYRX – Cryoport Inc, $879M
- JBIO – Jade Biosciences, Inc., $853M
- MLTX – MoonLake Immunotherapeutics, $813M
- PHAR – Pharming Group NV, $690M
- MDXG – MiMedx Group Inc, $670M
- AVR – Anteris Technologies Global Corp. Common Stock, $629M
- EVO – Evotec SE ADR, $478M
- TECX – Tectonic Therapeutic, Inc., $444M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- OFIX – Orthofix Medical Inc, $367M
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- CLPT – Clearpoint Neuro Inc, $277M
- QTTB – Q32 Bio Inc, $232M
- LRMR – Larimar Therapeutics Inc, $224M
- ORGO – Organogenesis Holdings Inc, $170M
- MDWD – Mediwound Ltd, $158M
- CHRS – Coherus BioSciences Inc, $156M
- HUMA – Humacyte Inc, $119M
- CUE – Cue Biopharma, $117M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- RANI – Rani Therapeutics Holdings Inc, $103M
- OSTX – OS Therapies Incorporated, $75.8M
- INKT – Mink Therapeutics Inc, $52.2M
- TELA – Tela Bio Inc, $47.4M
- XTNT – Xtant Medical Holdings Inc, $45.7M
- CELU – Celularity Inc, $44.8M
- CCEL – CryoCell International Inc, $38.3M
- GNTA – Genenta Science SpA ADR, $34.8M
- ELUT – Elutia Inc., $34.2M
- ATYR – aTyr Pharma, Inc., $16.8M
- GTBP – GT Biopharma Inc, $14.5M
- AEON – AEON Biopharma, Inc., $11.6M
- GDTC – CytoMed Therapeutics Limited Ordinary Shares, $11.1M
- TOVX – Theriva Biologics Inc., $9.9M
- OSRH – OSR Holdings Inc, $7.4M
- NVNO – enVVeno Medical Corp, $5.4M
- BRTX – BioRestorative Therapies Inc, $3.1M
- BCAB – Bioatla Inc, $2.5M
- SCNI – Scinai Immunotherapeutics Ltd, $826,686
- XAGE – Longevity Health Holdings, Inc., $277,235
- SCPX – Scorpius Holdings Inc, $12,228